サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：細胞株開発の世界市場：2023-2030年
市場調査レポート
商品コード
1380398

細胞株開発の世界市場：2023-2030年

Global Cell Line Development Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 210 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.97円
細胞株開発の世界市場：2023-2030年
出版日: 2023年09月27日
発行: Orion Market Research
ページ情報: 英文 210 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の細胞株開発市場は、予測期間（2023-2030年）にCAGR 9.6％で成長すると予測されています。細胞株開発は、バイオテクノロジーや製薬研究において重要なプロセスであり、治療用タンパク質、抗体、ワクチン、その他のバイオ医薬品を生産するための安定した高収量の細胞株を作製することを目的としています。最初のステップでは、適切な宿主細胞株を選択する必要があり、多くの場合、製品の特定の要件に応じて、哺乳類、昆虫、または微生物由来の宿主細胞株を選択します。

セグメント別の展望

世界の細胞株開発市場において、哺乳類のサブセグメントが大きなシェアを占めると予想されます。

ソースタイプのうち、哺乳類サブセグメントは世界の細胞株開発市場でかなりのシェアを占めると予想されます。このセグメントの成長は、モノクローナル抗体の作製に哺乳類細胞ソースが使用されているなどのいくつかの要因に起因しています。これらの細胞株は、人体内のタンパク質を彷彿とさせる複雑なタンパク質を産生し、カスタマイズされた医薬品の作製に役立っています。さらに、ヒトの組織やその他の生物学的成分は哺乳類の細胞株に容易に適応することができ、感染のリスクを下げることができます。例えば、2023年6月、Synthego社は、非営利の世界の生物学的材料および標準リソースセンターであるATCCとの画期的な提携を発表し、遺伝子編集アプリケーション用の哺乳類およびマウス細胞株の広範なコレクションを研究者に提供します。この提携は、ゲノム工学の専門知識と、信頼できる生物学的材料と標準のプロバイダーとして名高いATCCの評判を結びつけるものです。

地域別展望

世界の細胞株開発市場は、北米（米国、カナダ）、欧州（英国、イタリア、スペイン、ドイツ、フランス、その他欧州地域）、アジア太平洋地域（インド、中国、日本、韓国、その他アジア地域）、その他アジア太平洋地域（中東とアフリカ、その他南米）を含む地域別にさらに細分化されています。なかでもアジア太平洋地域は、ヘルスケアインフラの改善や同地域の政府による好意的な取り組みにより、世界市場で突出したシェアを占めると予想されています。

北米地域は世界の細胞株開発市場で大きなCAGRで成長する見込み

すべての地域の中で、北米地域は予測期間中にかなりのCAGRで成長すると予測されています。同地域の成長は、医療インフラの改善と、同地域におけるより良い研究と製品開発のための市場プレイヤーの戦略的イニシアチブの増加に起因しています。例えば、Lineage Cell Therapeutics, Inc.は2023年9月、Eterna Therapeutics Inc.との独占的オプション契約およびライセンス契約に基づき、新規の低免疫性人工多能性幹細胞（iPSC）株を作製するための特定の開発活動を開始すると発表しました。これは、2023年2月に発表された戦略的提携の次のステップとなるもので、エテルナは、中枢神経系（CNS）疾患およびその他の神経学的適応症を対象とした細胞移植製品候補への分化をリネージが評価する革新的な工学的低免疫iPSC株を開発しています。リネージュは、今回の買収を発表して以来、米国内外の神経学の専門家グループと開発戦略を検討してきました。これらの議論や競合情勢の評価の結果、情勢はエテルナが開発する初期細胞株に対する特定の遺伝子編集の選択を最終決定しました。これらの遺伝子編集には、CD8+T細胞による拒絶反応を抑制することで細胞株由来の製品候補の免疫原性を低下させることを目的としたB2M遺伝子の標的欠失、HLA-Eを過剰発現させ同種NK細胞反応を阻止することを目的としたHLA-E遺伝子の標的挿入、適応症における臨床的差別化と競争優位性を付与することを目的とした3つ目の非公開の編集が含まれます。リネージュは、これらの編集により、非免疫特権または非ヒト白血球抗原（HLA）適合の適応症を含め、編集細胞株の全体的な有用性が拡大し、競合他社が現在使用している他の細胞株との差別化がさらに進むと期待しています。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Corning Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • GE Healthcare
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Thermo Fisher Scientific Inc
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 細胞株開発の世界市場：製品タイプ別
    • 試薬・培地
    • 装置
    • アクセサリーと消耗品
  • 細胞株開発の世界市場：ソースタイプ別
    • 哺乳類
    • 非哺乳類
  • 細胞株開発の世界市場：エンドユーザー別
    • バイオ医薬品・バイオテクノロジー企業
    • 学術・研究機関
    • 受託研究機関
  • 細胞株開発の世界市場：細胞株別
    • 組み換え
    • ハイブリドーマ
    • 連続的
    • プライマリー

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Advanced Instruments
  • Berkeley Lights, Inc.
  • Boehringer Ingelheim International GmbH
  • Creative BioLabs.
  • Danaher Corp.
  • Fujifilm Holdings Corp
  • Horizon Discovery Ltd.
  • JSR Corp.
  • Lonza Group Ltd
  • Merck KGaA Corning Inc.
  • Rentschler Biopharma SE
  • Sartorius AG
  • Selexis SA
  • Sigma-Aldrich Corp
  • WuXi PharmaTech
図表

LIST OF TABLES

  • 1. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 2. GLOBAL REAGENT AND MEDIA FOR CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 3. GLOBAL EQUIPMENT FOR CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL ACCESSORIES AND CONSUMABLES FOR CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 6. GLOBAL MAMMALIAN IN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 7. GLOBAL NON-MAMMALIAN IN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION,2022-2030 ($ MILLION)
  • 8. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 9. GLOBAL CELL LINE DEVELOPMENT FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL CELL LINE DEVELOPMENT FOR ACADEMICS AND RESEARCH INSTITUTES MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL CELL LINE DEVELOPMENT FOR CONTRACT RESEARCH ORGANIZATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)
  • 13. GLOBAL RECOMBINANT CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 14. GLOBAL HYBRIDOMAS CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL CONTINUOUS CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL PRIMARY CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 19. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)
  • 23. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 24. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 25. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 26. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 27. EUROPEAN CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)
  • 28. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 30. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 31. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 32. ASIA- PACIFIC CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 34. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY PRODUCT TYPE, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY SOURCE TYPE, 2022-2030 ($ MILLION)
  • 36. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 37. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY CELL LINES, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY PRODUCT TYPE, 2022 VS 2030 (%)
  • 2. GLOBAL REAGENT AND MEDIA FOR CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL EQUIPMENT FOR CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL ACCESSORIES AND CONSUMABLES FOR CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY SOURCE TYPE, 2022 VS 2030 (%)
  • 6. GLOBAL MAMMALIAN IN CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL NON-MAMMALIAN IN CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY END-USER, 2022 VS 2030 (%)
  • 9. GLOBAL CELL LINE DEVELOPMENT FOR BIOPHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL CELL LINE DEVELOPMENT FOR ACADEMICS AND RESEARCH INSTITUTES MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL CELL LINE DEVELOPMENT FOR CONTRACT RESEARCH ORGANIZATIONS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY CELL LINES, 2022 VS 2030 (%)
  • 13. GLOBAL RECOMBINANT IN CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 14. GLOBAL HYBRIDOMAS CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL CONTINUOUS CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL PRIMARY CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL CELL LINE DEVELOPMENT MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. US CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 19. CANADA CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 20. UK CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. FRANCE CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. GERMANY CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. ITALY CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. SPAIN CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. REST OF EUROPE CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. INDIA CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. CHINA CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. JAPAN CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. SOUTH KOREA CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. REST OF ASIA-PACIFIC CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. REST OF THE WORLD CELL LINE DEVELOPMENT MARKET SIZE, 2022-2030 ($ MILLION)
目次
Product Code: OMR2027859

Title: Global Cell Line Development Market Size, Share & Trends Analysis Report by Product Type (Reagent and Media, Equipment and Accessories and Consumables), by Source Type (Mammalian and Non-mammalian), by End User (Biopharmaceutical and Biotechnology Companies, Contract Research Organizations and Academics and Research Institutes) and by Cell Line (Recombinant, Hybridomas, Continuous and Primary),Forecast Period (2023-2030).

The global Cell Line Development market is anticipated to grow at a CAGR of 9.6% during the Forecast Period (2023-2030). Cell line development is a critical process in biotechnology and pharmaceutical research, aimed at creating stable and high-yielding cell lines to produce therapeutic proteins, antibodies, vaccines, and other biopharmaceuticals. The initial step involves choosing a suitable host cell line, often derived from mammalian, insect, or microbial sources, depending on the specific requirements of the product.

Segmental Outlook

The global Cell Line Development market is segmented on the product type, Source type, End user, and cell line. Based on the product type, the market is sub-segmented into Reagent and Media, Equipment and Accessories and Consumables. Based on source type, the market is sub-segmented into Mammalian and Non-mammalian. Based on the end user, the market is sub-segmented into Biopharmaceutical and Biotechnology Companies, Contract Research Organizations and Academics and Research Institutes. And based on cell line, the market is segmented into Recombinant, Hybridomas, Continuous and Primary. Among the cell line, the Recombinant sub-segment is anticipated to hold a considerable share of the market, owing to rising demand for biologics to treat cancer and autoimmune illnesses.

The Mammalian Sub-Segment is Anticipated to Hold a Considerable Share of the Global Cell Line Development Market

Among the Source Type, the Mammalian sub-segment is expected to hold a considerable share of the global Cell Line Development market. This segmental growth is attributed to several factors such as, mammalian cell sources are being used to create monoclonal antibodies. These cell lines produce intricate proteins that are reminiscent of those in the human body, aiding in the creation of customized medications. Additionally, human tissues and other biological components can easily adapt to mammalian cell lines, lowering the risk of infection. For instance, In June 2023, Synthego, announced a groundbreaking partnership with ATCC, the premier non-profit global biological materials and standards resource center, to provide researchers with an extensive collection of mammalian and mouse cell lines for gene editing applications, including Express Cell Pools to increase speed to results. This alliance brings together its expertise in genome engineering and ATCC's renowned reputation as a trusted provider of authenticated biological materials and standards.

Regional Outlook

The global Cell Line Development market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia pacific is anticipated to hold a prominent share of the market across the globe, owing to improving healthcare infrastructure, and favorable initiatives by government in the region.

The North America Region is Expected to Grow at a Significant CAGR in the Global Cell Line Development Market

Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to improving medical infrastructure and increasing strategic initiatives by market players for better research and product development in the regions. For instance, in September 2023, Lineage Cell Therapeutics, Inc., announced the initiation of certain development activities to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line under the Company's exclusive option and license agreement with Eterna Therapeutics Inc. This marks the next step under the strategic collaboration announced in February 2023, under which Eterna is developing innovative engineered hypoimmune iPSC lines that Lineage will evaluate for differentiation into cell transplant product candidates for central nervous system (CNS) diseases and other neurology indications. Since announcing the deal earlier, Lineage has evaluated its development strategy with a group of leading neurology experts in the US and abroad. As a result of these and other discussions, and an assessment of the competitive landscape, Lineage finalized its selection of specific gene edits for the initial cell lines to be developed by Eterna. The edits include the targeted deletion of the B2M gene, designed to reduce the immunogenicity of product candidates derived from the lines by inhibiting rejection by CD8+ T cells; the targeted insertion of the HLA-E gene, designed to overexpress HLA-E and prevent the allogeneic NK cell response, and a third undisclosed edit intended to confer clinical differentiation and a competitive advantage in the applicable indications. Lineage expects that these edits would expand the edited cell lines' overall utility, including for non-immune privileged or non-human leukocyte antigen (HLA) matched indications and will further differentiate the cell line from others currently in use by competitors.

Market Players Outlook

The major companies serving the Cell Line Development market include: Advanced Instruments, Berkeley Lights, Boehringer Ingelheim International GmbH, Creative BioLabs., Danaher, Fujifilm Holdings Corp, Horizon Discovery Ltd., JSR Corp, Lonza, Merck KGaA Corning Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2019, Solentim, the cell line development (CLD) imaging instrumentation producer, and SAL Scientific, a provider of growth-enhancing animal-free cell culture reagents, announced a new strategic partnership. The collaboration will further optimise CLD workflow by supplying novel supplements which substantially improve cell growth. Solentim will act as the exclusive distributor for the SAL Scientific 'Insti' product range. Cells grown in chemically defined, animal component-free media can be susceptible to impaired growth and viability, especially when subjected to stress.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global Cell Line Development market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Corning Inc.
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. GE Healthcare
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Thermo Fisher Scientific Inc
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Cell line development Market by Product Type
    • 4.1.1. Reagent and Media
    • 4.1.2. Equipment
    • 4.1.3. Accessories and Consumables
  • 4.2. Global Cell line development Market by Source Type
    • 4.2.1. Mammalian
    • 4.2.2. Non-mammalian
  • 4.3. Global Cell line development Market by End-User
    • 4.3.1. Biopharmaceutical and Biotechnology companies
    • 4.3.2. Academics and Research Institutes
    • 4.3.3. Contract Research Organizations
  • 4.4. Global Cell line development Market by Cell Line
    • 4.4.1. Recombinant
    • 4.4.2. Hybridomas
    • 4.4.3. Continuous
    • 4.4.4. Primary

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Advanced Instruments
  • 6.2. Berkeley Lights, Inc.
  • 6.3. Boehringer Ingelheim International GmbH
  • 6.4. Creative BioLabs.
  • 6.5. Danaher Corp.
  • 6.6. Fujifilm Holdings Corp
  • 6.7. Horizon Discovery Ltd.
  • 6.8. JSR Corp.
  • 6.9. Lonza Group Ltd
  • 6.10. Merck KGaA Corning Inc.
  • 6.11. Rentschler Biopharma SE
  • 6.12. Sartorius AG
  • 6.13. Selexis SA
  • 6.14. Sigma-Aldrich Corp
  • 6.15. WuXi PharmaTech